Ipamorelin: A Research Overview

Research-use context. Educational summary for laboratory audiences. Not medical advice, a dosing guide, or a recommendation for human use. Ipamorelin is investigational and not FDA-approved for human use, and GH secretagogues are prohibited in sport by WADA (2026 Prohibited List, section S2). All VANTA products are sold strictly for in-vitro and laboratory research use only.

TL;DR: Ipamorelin is a synthetic, selective growth hormone secretagogue (a pentapeptide) that triggers GH release through the ghrelin receptor (GHS-R1a) with comparatively little effect on cortisol or prolactin. It is most often studied alongside the GHRH analog CJC-1295. It is investigational, not FDA-approved, and prohibited in sport by WADA.

Last reviewed: July 2026.

What is Ipamorelin?

Ipamorelin is a synthetic growth hormone secretagogue (GHS) — a pentapeptide that stimulates GH release by acting on the ghrelin receptor (GHS-R1a), a pathway parallel to and distinct from the GHRH pathway. It is frequently described in the literature as a selective secretagogue: relative to earlier GHS compounds, it is reported to stimulate GH release with comparatively little effect on cortisol or prolactin. It is supplied as a lyophilized powder for laboratory reconstitution.

How does Ipamorelin work?

Ipamorelin works by binding GHS-R1a (the ghrelin receptor) on pituitary cells, promoting pulsatile GH release that mimics the body’s natural secretory pattern. Because GHRH analogs (e.g. CJC-1295) and ghrelin-receptor secretagogues act through separate mechanisms — sometimes framed as “pressing the accelerator” (GHRH) while “releasing the brake” (ghrelin pathway / somatostatin modulation) — the two classes are often studied together for a combined effect on GH pulsatility.

What does the research on Ipamorelin actually show?

Ipamorelin’s defining research finding is selectivity: early characterization described it as a potent GH secretagogue with a notably cleaner profile than earlier compounds. The evidence base is largely preclinical and mechanistic, and rigorous trials of the popular CJC-1295 combination remain limited.

Selectivity is the headline finding. Early characterization (Raun et al., 1998) described Ipamorelin as a potent, selective GH secretagogue with a clean profile relative to other GHS compounds of the era — the property most consistently cited.
The evidence is largely preclinical and mechanistic / older. Much of the foundational work is animal and receptor pharmacology; large, long-term human outcome trials are not the basis of the current interest.
Combination claims outrun combination data. The CJC-1295 + Ipamorelin pairing is mechanistically reasonable and widely discussed, but rigorous trials of the specific combination are limited; most support comes from the separate component literatures and the general GHRH+GHS synergy concept.

How does Ipamorelin compare to CJC-1295 and other GH peptides?

Ipamorelin is the GH-secretagogue most often paired with the GHRH analog CJC-1295 in research discussion. Related compounds in the broader GHS class include GHRP-6, GHRP-2, and the orally active MK-677 (ibutamoren).

What is the regulatory status of Ipamorelin in 2026?

As of mid-2026, Ipamorelin is not FDA-approved and has not completed the drug approval pathway. It was among the peptides reported removed from the FDA’s Category 2 restricted list in 2026 (effective April 23, 2026), restoring a potential compounding pathway under physician prescription. As with CJC-1295, three separate things are commonly confused:

Coming off the Category 2 list is not FDA approval.
Ipamorelin is not on the July 23–24, 2026 Pharmacy Compounding Advisory Committee 503A agenda (which covers BPC-157, KPV, TB-500, MOTS-C, DSIP, Semax, and Epitalon).
It remains WADA-prohibited (2026 List, Section S2).

VANTA supplies Ipamorelin for in-vitro and laboratory research use only — a distinct context from prescribed compounded preparations.

Laboratory handling

Storage (lyophilized): cold, protected from light; long-term at −20 °C.
After reconstitution: refrigerated (2–8 °C), used within the lab’s protocol window.
Verification: confirm identity/purity against the batch COA (HPLC, mass spec).

VANTA supplies Ipamorelin as a ≥99% purity research peptide with a batch-specific COA. See our Certificates of Analysis page.

Frequently asked (research) questions

Why is Ipamorelin called “selective”? It is reported to stimulate GH release with comparatively little effect on cortisol and prolactin, unlike some earlier GH secretagogues.

How does it differ from CJC-1295? Different receptors: Ipamorelin acts on the ghrelin receptor (GHS-R1a); CJC-1295 is a GHRH-receptor analog. They are studied together because the pathways are complementary.

Is Ipamorelin FDA-approved or legal in 2026? No, Ipamorelin is not FDA-approved. It was removed from the FDA’s Category 2 restricted list in 2026, which may restore compounding access under prescription, but that is not drug approval — and VANTA’s material is sold strictly for research use only.

References

Raun K, Hansen BS, Johansen NL, et al. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998;139(5):552–561. doi:10.1530/eje.0.1390552.
Gobburu JV, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a GH secretagogue, in human volunteers. (GHS pharmacology literature.)
Teichman SL, et al. Prolonged stimulation of GH and IGF-I by CJC-1295… J Clin Endocrinol Metab. 2006;91(3):799–805. (combination/context reference.)
WADA. Prohibited List 2026 — Section S2.

Verify each source independently. This summary is research context only and does not describe or recommend human use.